AbbVie Lowers Full-Year 2025 EPS Guidance Due to $1.3 Billion Q4 IPR&D Expense
Summary
AbbVie revised its full-year 2025 adjusted diluted EPS guidance to $9.90-$9.94, down from $10.61-$10.65, primarily due to a $1.3 billion acquired IPR&D and milestones expense incurred in the fourth quarter of 2025.
Key Events
-
Revised Full-Year 2025 EPS Guidance
AbbVie's full-year 2025 adjusted diluted EPS guidance is now $9.90 - $9.94, a reduction from the previously announced range of $10.61 - $10.65.
-
Q4 2025 IPR&D Expense Impact
The company expects to include $1.3 billion in acquired IPR&D and milestones expense on a pre-tax basis for the fourth quarter of 2025, resulting in an unfavorable impact of $0.71 per share on both GAAP and adjusted non-GAAP diluted EPS.
-
Updated Q4 2025 EPS Guidance
The adjusted diluted EPS guidance for Q4 2025, including the IPR&D expense, is now projected to be $2.61 - $2.65.
Analysis
AbbVie's updated guidance reflects a significant, albeit non-recurring, expense related to acquired in-process research and development (IPR&D) and milestones. While the $1.3 billion pre-tax charge for Q4 2025 is substantial and reduces the full-year EPS outlook, the company notes that such expenses are not typically forecasted due to their uncertain nature and timing. Investors will need to consider whether this IPR&D investment is strategically beneficial for future growth, despite the immediate negative impact on reported earnings.
At the time of this filing, ABBV was trading at $229.50 on NYSE in the Life Sciences sector, with a market capitalization of approximately $412.5B. The 52-week trading range was $164.39 to $244.81. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.